The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Treatment of Scedosporiosis with Voriconazole: Clinical Experience with 107 Patients
Open accessAbstract
The efficacy of voriconazole in 107 patients with scedosporiosis was analyzed. Principal infection sites were the lungs/sinuses (24%), central nervous system (CNS) (20%), and bone (18%), while 21% of patients had disseminated infection. Solid organ transplantation (22%), hematological malignancy (21%), and surgery/trauma (15%) were the predominant underlying conditions. A successful therapeutic response was achieved in 57% of patients (median, 103 therapy days), with >98% of those responding receiving ≥28 days of therapy. Patients receiving primary therapy showed a 61% response versus 56% for the others. The best therapeutic responses were seen for skin/subcutaneous (91%) or bone (79%) infections, and the lowest for CNS infections (43%). Patients without major immune suppression (72%) or those with solid organ transplantation (63%) or various hematological conditions (60%) showed the best responses by underlying condition. Median known survival time was 133 days (therapy successes, 252 days; failures, 21 days). In all, 43 (40%) patients died, 73% due to scedosporiosis. Patients with Scedosporium prolificans infection had significantly reduced survival times ( P = 0.0259) and were more likely to die from fungal infection ( P = 0.002) than were Scedosporium apiospermum -infected patients. In a subset of 43 patients where voriconazole baseline MICs were available, response to voriconazole was higher for S. apiospermum -infected patients (54% response; MIC 50 , 0.25 μg/ml) than for S. prolificans -infected patients (40% response; MIC 50 , 4.0 μg/ml). Voriconazole demonstrated clinically useful activity in the treatment of both S. apiospermum and S. prolificans infections and was well tolerated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
De Pauw, B., Walsh, T. J., Donnelly, J. P., Stevens, D. A., Edwards, J. E., Calandra, T., Pappas, P. G., Maertens, J., Lortholary, O., Kauffman, C. A., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/588660 · Cited by 4,917
Voriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis
Herbrecht, R., Denning, D. W., Patterson, T. F., Bennett, J. E., Greene, R. E., Oestmann, J.-W., Kern, W. V., Marr, K. A., Ribaud, P., Lortholary, O., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020191 · Cited by 3,304
Self-citationAscioglu, S., Rex, J. H., de Pauw, B., Bennett, J. E., Bille, J., Crokaert, F., Denning, D. W., Donnelly, J. P., Edwards, J. E., Erjavec, Z., et al. (2002) · Clinical Infectious Diseases · doi:10.1086/323335 · Cited by 2,331
(2016) · Lung Transplantation · doi:10.3109/9781439802571-25 · Cited by 2,157
de Hoog, S., Guarro, J., Gené, J., & Figueras, M. J. (2000) · UvA-DARE (University of Amsterdam) · Cited by 1,427
Voriconazole Treatment for Less‐Common, Emerging, or Refractory Fungal Infections
Perfect, J. R., Marr, K. A., Walsh, T. J., Greenberg, R. N., DuPont, B., de la Torre‐Cisneros, J., Just‐Nubling, G., Schlamm, H. T., Lutsar, I., Espinel‐Ingroff, A., et al. (2003) · Clinical Infectious Diseases · doi:10.1086/374557 · Cited by 680
Self-citationMaertens, J., Raad, I., Petrikkos, G., Boogaerts, M., Selleslag, D., Petersen, F. B., Sable, C. A., Kartsonis, N. A., Ngai, A., Taylor, A., et al. (2004) · Clinical Infectious Diseases · doi:10.1086/423381 · Cited by 658
Walsh, T. J., Hiemenz, J. W., Seibel, N. L., Perfect, J. R., Horwith, G., Lee, L., Silber, J. L., DiNubile, M. J., Reboli, A., Bow, E., et al. (1998) · Clinical Infectious Diseases · doi:10.1086/516353 · Cited by 629
Pharmacokinetics and Safety of Voriconazole following Intravenous- to Oral-Dose Escalation Regimens
Purkins, L., Wood, N., Ghahramani, P., Greenhalgh, K., Allen, M. J., & Kleinermans, D. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.8.2546-2553.2002 · Cited by 415
Husain, S., Munoz, P., Forrest, G., Alexander, B. D., Somani, J., Brennan, K., Wagener, M. M., & Singh, N. (2005) · Clinical Infectious Diseases · doi:10.1086/426445 · Cited by 401
Cited by
Nett, J. E., & Andes, D. R. (2016) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2015.10.012 · Cited by 351
Epidemiology and outcome of Scedosporium prolificans infection, a review of 162 cases
Rodriguez-Tudela, J. L., Rodriguez-Tudela, J. L., Berenguer, J., Guarro, J., Kantarcioglu, A. S., Horre, R., Sybren De Hoog, G., & Cuenca-Estrella, M. (2009) · Medical Mycology · doi:10.1080/13693780802524506 · Cited by 269
Scedosporium and Lomentospora: an updated overview of underrated opportunists
Ramirez-Garcia, A., Pellon, A., Rementeria, A., Buldain, I., Barreto-Bergter, E., Rollin-Pinheiro, R., de Meirelles, J. V., Xisto, M. I. D. S., Ranque, S., Havlicek, V., et al. (2018) · Medical Mycology · doi:10.1093/mmy/myx113 · Cited by 264
Cordonnier, C., Rovira, M., Maertens, J., Olavarria, E., Faucher, C., Bilger, K., Pigneux, A., Cornely, O. A., Ullmann, A. J., Bofarull, R. M., et al. (2010) · Haematologica · doi:10.3324/haematol.2009.020073 · Cited by 137
Self-citation
Metadata
- Authors
- Troke, P., Aguirrebengoa, K., Arteaga, C., Ellis, D., Heath, C. H., Lutsar, I., Rovira, M., Nguyen, Q., Slavin, M., & Chen, S. C. A.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2008-05
- Volume
- 52
- Issue
- 5
- Pages
- 1743-1750
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2077919952
- Cited by
- 294
- References
- 45
- FWCI
- 13.24
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Treatment of Scedosporiosis with Voriconazole: Clinical Experience with 107 Patients. https://app.cochat.ai/papers/10.1128/aac.01388-07
- The paper
- Troke, P., Aguirrebengoa, K., Arteaga, C., Ellis, D., Heath, C. H., Lutsar, I., Rovira, M., Nguyen, Q., Slavin, M., & Chen, S. C. A. (2008). Treatment of Scedosporiosis with Voriconazole: Clinical Experience with 107 Patients. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01388-07
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.